IPO - Check IPO Date, Price, Lot Size

Senores Pharmaceuticals Ltd IPO

We are a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms. Our Regulated Markets business is primarily focused on the Regulated Markets of US, Canada, and United Kingdom. We have adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and as of March 31, 2024, we have received approvals for 19 ANDAs. We develop and manufacture generic pharmaceutical products across various therapeutic areas for the Emerging Markets in the B2B segment, having a presence across 43 countries. We also operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.

Senores Pharmaceuticals Ltd IPO Details

Total Shares Offered

₹ 1,48,87,723

Offer to Public

21,00,000

Retail Max (Shares)

₹ 14,81,272

Pre Issue Promoters Holding

₹ 2,21,76,079

Exchange

BSE

Issue size

₹ 582.11 Cr

IPO Open Date

Dec 20, 2024

Close Date

Dec 24, 2024

Lot Size

Min Investment

₹ 14,136

Issue Type

Book Building

Listing Date

Dec 30, 2024

Senores Pharmaceuticals Ltd IPO Dates

Dec 20, 2024

Opening date

Dec 24, 2024

Closing date

Dec 26, 2024

Basis of Allotment

Dec 26, 2024

Initiation of Refunds

Dec 27, 2024

Credit of Shares

Dec 30, 2024

Listing date

Details

Sector	Type
Sector	Pharmaceuticals - Indian - Formulations
Sub Sector	NA
Issue Type	Book Building

Subscription Status

*Values are in Lakhs

Investor Type	Subscription Times	Shares Offered*	Shares Bid*
QIB	39.14x	11109543	434778102
NII	100.35x	2221909	222963632
Retail	93.16x	1481272	137996278
Employee	19.92x	75000	1494122
Total	53.55x	14887723	797232134

Investor Type

QIB

NII

Retail

Employee

Total

Subscription Times

39.14x

100.35x

93.16x

19.92x

53.55x

11109543

2221909

1481272

75000

14887723

434778102

222963632

137996278

1494122

797232134

Senores Pharmaceuticals Ltd Financial Status

Income Statement

Particulars (In Rs. Crores)

Balance Sheet

Particulars (In Rs. Crores)

Particulars (in Rs. Crores)	FY23	FY22	FY21
Revenue from operations	377.98	214.52	35.34
EBITDA	11.27	6.11	3.80
PAT	3.69	0.81	1.20
Total Assets	413.12	40.39	27.86
Share Capital	46.05	30.51	9.82
Total Borrowings	71.86	18.32	11.93
Operating Activities (Net Cash)	6.77	2.85	2.13
Investing Activities (Net Cash)	70.37	63.11	-3.10
Financing Activities (Net Cash)	71.86	18.32	11.93
Net Cashflow	359.72	10.45	0.09

About Senores Pharmaceuticals Ltd

Our Company was originally incorporated as Senores Pharmaceuticals Private Limited a private limited company under the Companies Act, 2013 through a certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to Senores Pharmaceuticals Limited upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023 and a special resolution passed in the general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.

As per the F&S Report, the US pharmaceutical market increased from USD 589.0 billion in CY 2021 to USD 711.0 billion in CY 2023. The US CDMO market grew from USD 36.3 billion in CY 2021 to USD 44.7 billion in CY 2023. The Emerging pharmaceutical market rose from USD 354.3 billion in CY 2021 to USD 376.3 billion in CY 2023. The Indian hospital channel market expanded from USD 3.9-4.7 billion in CY 2021 to USD 4.7-5.7 billion in CY 2023 while the India API market increased from USD 11.5 billion to USD 13.1 billion in the same period.

Peer Comparison:

Ajanta Pharma Ltd
Alembic Pharmaceuticals Ltd
Caplin Point Laboratories Ltd
Gland Pharma Ltd
Strides Pharma Science Ltd

Senores Pharmaceuticals Ltd Key Points

Strengths

Ability to cater to the Regulated Markets of US, Canada and the United Kingdom through our US FDA approved formulation manufacturing facility in the US.

Distinct niche product portfolio built in a short span for Regulated Markets of US, Canada and the United Kingdom.

Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom.

Presence in the Emerging Markets with a product portfolio, including specialty or complex products.

R&D capabilities driving our differentiated portfolio of products.

Risk

The company business is dependent on the sale of its products through third party marketing partners and distributors. The loss of one or more marketing partners or distributors, the deterioration of their financial condition or prospects, or a reduction in their demand for its products or the company inability to maintain and increase the number of its arrangements for the marketing and distribution of the company products could adversely affect its business, results of operations, financial conditions and cash flows.

The company business is dependent on the sale of its products and continued growth of the Regulated Markets. Decrease in market growth for its product or failures to respond to change in market conditions could adversely affect its business, results of operations, financial conditions and cash flows.

Failures to comply with the quality standards and technical specifications prescribed by its customers may lead to loss of business from such customers and could negatively impact its business, results of operations and financial condition, including cancellation of existing and future orders which may expose it to warranty claims.

Strategy

Enhance market presence of our Marketed Products in North America and other Regulated Markets.

Launch of products in the US with New Drug Applications (NDA) approval.

Expanding into new Regulated and Emerging Markets.

Strategic alliance for CMO/ CDMO in Regulated Markets.

Pursuing an integrated approach to our business by enhancing our capabilities for greater backward integration.

How To Apply for Senores Pharmaceuticals Ltd IPO Online?

Step 1:

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

FAQs on IPO (Initial Public Offering)

What is the issue size of the Senores Pharmaceuticals Ltd IPO?

Senores Pharmaceuticals Ltd's IPO offers shares for up to 500 It begins on Dec 20, 2024 and ends on Dec 24, 2024.

What is the price of the Senores Pharmaceuticals Ltd IPO?

The price of Senores Pharmaceuticals Ltd IPO ranges between ₹372 to ₹391 per share.

What are the open and close dates for the Senores Pharmaceuticals Ltd IPO?

The Senores Pharmaceuticals Ltd IPO opens on Dec 20, 2024 and closes on Dec 24, 2024.

When will the Senores Pharmaceuticals Ltd IPO be allotted?

The allotment for the Senores Pharmaceuticals Ltd IPO will be finalised on Dec 26, 2024. The shares will be listed on BSE and NSE on Dec 30, 2024.

What is the minimum lot size required for Senores Pharmaceuticals Ltd IPO?

The minimum lot size for Senores Pharmaceuticals Ltd IPO is 38 shares, priced between ₹372 to ₹391 per share.

What is the GMP of Senores Pharmaceuticals Ltd IPO?

The GMP (Grey Market Premium) of Senores Pharmaceuticals Ltd IPO fluctuates based on market demand and sentiment.

How do you check the allotment status of Senores Pharmaceuticals Ltd IPO?

To check the allotment status of Senores Pharmaceuticals Ltd IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

Where is the Senores Pharmaceuticals Ltd IPO getting listed?

The Senores Pharmaceuticals Ltd IPO is getting listed on the BSE and NSE. Bidding opens on Dec 20, 2024, and closes on Dec 24, 2024. The allotment is finalised on Dec 26, 2024.

How do you apply for the Senores Pharmaceuticals Ltd IPO?

To apply for the Senores Pharmaceuticals Ltd IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.